ERBB2 and breast cancer: In this clinical scenario, novel agents have been incorporated to the armamentarium of breast cancer patients with HER2 positive tumors, including the kinase inhibitor lapatinib, the anti-HER2 antibody pertuzumab or the antibody drug conjugate T-DM1 [7–9].